Pharmacological study of the novel compound FLZ against experimental Parkinson's models and its active mechanism.
about
P-glycoprotein mediated efflux limits the transport of the novel anti-Parkinson's disease candidate drug FLZ across the physiological and PD pathological in vitro BBB modelsProtective effects of compound FLZ on beta-amyloid peptide-(25-35)-induced mouse hippocampal injury and learning and memory impairment.A novel cyclic squamosamide analogue compound FLZ improves memory impairment in artificial senescence mice induced by chronic injection of D-galactose and NaNO2.An in vivo microdialysis study of FLZ penetration through the blood-brain barrier in normal and 6-hydroxydopamine induced Parkinson's disease model rats.Squamosamide derivative FLZ protects dopaminergic neurons against inflammation-mediated neurodegeneration through the inhibition of NADPH oxidase activity.Squamosamide derivative FLZ inhibits TNF-α-induced ICAM-1 expression via down-regulation of the NF-κB signaling pathway in ARPE-19 cells.Compound FLZ inhibits lipopolysaccharide-induced inflammatory effects via down-regulation of the TAK-IKK and TAK-JNK/p38MAPK pathways in RAW264.7 macrophagesProtective effects of compound FLZ, a novel synthetic analogue of squamosamide, on beta-amyloid-induced rat brain mitochondrial dysfunction in vitro.FLZ inhibited γ-secretase selectively and decreased Aβ mitochondrial production in APP-SH-SY5Y cells.Novel squamosamide derivative (compound FLZ) attenuates Abeta25-35-induced toxicity in SH-SY5Y cells.FLZ, synthetic squamosamide cyclic derivative, attenuates memory deficit and pathological changes in mice with experimentally induced aging.
P2860
Q28540914-58012129-7711-4E5F-BAB6-7A8958BE12E2Q33244612-238547AE-E6BC-4A01-8361-6475F06D0ACDQ33304383-E6FFB1CE-CC91-47A7-96A9-6966069EDDA9Q33876743-99413720-B537-4412-A893-D2435DCE38BFQ36700366-0EC83821-D840-46AF-AF4B-1DB63DB23EBAQ38828062-504940AE-2FBA-4A12-B6D7-01EEC797E25DQ39014120-CB77FFD4-9994-4973-B901-E2C9018DD224Q39019667-9514B24B-4E23-432D-AA04-594C8704E383Q39090889-6A0EA374-3ACB-4B88-A4AE-457B3D5C268BQ40021372-5BD2A1C6-8CE9-444D-9743-1ABB2E1260D4Q48598438-51A306E4-2B60-4701-9764-766C58D1A6EF
P2860
Pharmacological study of the novel compound FLZ against experimental Parkinson's models and its active mechanism.
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
2005年论文
@zh
2005年论文
@zh-cn
name
Pharmacological study of the n ...... dels and its active mechanism.
@ast
Pharmacological study of the n ...... dels and its active mechanism.
@en
type
label
Pharmacological study of the n ...... dels and its active mechanism.
@ast
Pharmacological study of the n ...... dels and its active mechanism.
@en
prefLabel
Pharmacological study of the n ...... dels and its active mechanism.
@ast
Pharmacological study of the n ...... dels and its active mechanism.
@en
P2093
P356
P1476
Pharmacological study of the n ...... dels and its active mechanism.
@en
P2093
Geng Tao Liu
Huailing Wei
Weihong Feng
P2888
P304
P356
10.1385/MN:31:1-3:295
P577
2005-01-01T00:00:00Z
P6179
1045709945